com.insightguru.giraffe.server.utils.PresentationUtil$PresentationTitle@7a8b9dc
This site requires JavaScript to function properly.
For help enabling JavaScript click here.
Here are some sample widgets you could interact with from this dashboard:
(1) Revenues expected to be well ahead of consensus estimates
Trefis estimates PFE's Q2 2021 revenues to be $21.7 Bil, well ahead of the consensus estimate of $18.5 Bil
Estimated Revenues - 2021Q2(E)
Trefis Estimates for Pfizer Revenues:
Expected Change (YoY): 83.9%
The chart to the right highlights trends in Pfizer's Revenues over the last four quarters along with our forecast for Q2 2021.
Quarterly Revenue Trend
(2) EPS likely to comfortably beat consensus estimates
PFE's Q2 2021 earnings per share (EPS) expected to be $1.12 per Trefis analysis, comfortably beating the consensus estimate of $0.96 by 17%
Estimated EPS- 2021Q2(E)
Trefis Estimates for Pfizer EPS:
Expected Change (YoY): 80.6%
The chart to the right highlights trends in PFE's EPS over the last four quarters along with our forecast for Q2 2021.
Quarterly EPS Trend
(3) Stock price estimate 20% higher than current market price
Trefis maintains a fair value of $50 for PFE's stock as opposed to the current market price of roughly $42.
PFE Stock Price
The Trefis Price Estimate for Pfizer stock represents the fair value for the company's stock over a one-year horizon.
Details about the chances of a rise in PFE stock in the near term can be found in a separate interactive dashboard.
The chart to the right highlights trends in PFE's stock price at the end of each of the last four quarters as well as the current stock price.
Stock Price (Quarter End)
#1. Estimating Pfizer's Total Revenues:
Pfizer's Revenues have seen a slight increase of 2.7% from around $41 Bil in FY2018 to $42 Bil in FY2020 and we expect it to increase to $80 Bil in FY2021
Total Revenue
A Separate Interactive Dashboard Analysis On Pfizer's Revenues Details How The Company Makes Money.
#2. Deriving Pfizer's Adjusted Net Income:
Pfizer's Adjusted Net Income has decreased from around $18 Bil in FY2018 to $13 Bil in FY2020 and we expect it to increase to $26 Bil in FY2021
This change is likely to be led by higher revenues and improved margins.
A Separate Interactive Dashboard Analysis On Pfizer's Margins Highlights The Company's Various Expenses Components In Detail.
Adjusted Net Income [AxB]
Adjusted Net Income Margin [A]
Total Revenue [B]
#3. Determining Pfizer's Adjusted EPS:
Pfizer's Adjusted EPS has decreased from $3.01 in FY2018 to $2.22 in FY2020 and we expect it to increase to $4.75 in FY2021
The change in EPS can be attributed to an increase in adjusted net income and a lower expected share count due to stock repurchases.
Adjusted EPS [A÷B]
Adjusted Net Income [A]
Shares Outstanding [B]
#4. Estimating Pfizer's Share Price:
Our Price Estimate of $50 For Pfizer's Stock is based on our Detailed Valuation Model, and implies a 10.5x P/E Multiple on expected FY2021 Adjusted EPS of $4.75
Trefis Price Estimate [AxB]
Adjusted EPS [A]
P/E Multiple [B]